Price Target Update on St. Jude Medical (NYSE:STJ)

St. Jude Medical (NYSE:STJ) stock is expected to deviate a maximum of $11.55 from the average target price of $73.81 for the short term period. 18 Street Experts have initiated coverage on the stock with the most promising target being $91 and the most muted being $54.

Other Equity analysts have also commented on the company shares. Brokerage firm Barclays downgrades its rating on St. Jude Medical (NYSE:STJ). As per the latest information, the brokerage house raises the price target to $80 per share from a prior target of $74. The shares have been rated Equal-weight. Previously, the analysts had a Overweight rating on the shares. The rating by the firm was issued on May 11, 2016.

St. Jude Medical (NYSE:STJ): stock turned positive on Thursday. Though the stock opened at $77.95, the bulls momentum made the stock top out at $78.49 level for the day. The stock recorded a low of $77.92 and closed the trading day at $78.49, in the green by 1.06%. The total traded volume for the day was 1,978,545. The stock had closed at $77.67 in the previous days trading.

The company shares have rallied 4.05% from its 1 Year high price. On Jul 21, 2015, the shares registered one year high at $80.84 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $76.85 and the 200 Day Moving Average price is recorded at $62.25. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (VP, Global Quality) of St Jude Medical Inc, Fecho Jeff had sold 10,408 shares worth of $538,198 in a transaction dated February 5, 2016. In this transaction, 10,408 shares were sold at $51.71 per share.

St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems, bradycardia pacemaker systems, atrial fibrillation (AF) products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems), vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, heart failure monitoring device and other vascular accessories), structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.